Novo Nordisk Boosts Supply of Weight-Loss Drug Wegovy Amid Growing Demand

Novo Nordisk has boosted the supply of its weight loss drug Wegovy, allowing more patients in the U.S. to start taking the medication. The increased supply of the lowest dose aims to address previous restrictions that prevented new patients from beginning treatment. The company's efforts to maintain supply for existing users led to supply shortages for new patients, prompting some to be prescribed off-label alternatives. Novo Nordisk also noted improvements in insurance coverage for Wegovy, potentially benefiting around 50 million people in the U.S. with obesity.